logo-loader
viewReNeuron Group PLC

ReNeuron pleased to secure podium presentation for stroke data at US conference

Michael Hunt, CFO at ReNeuron Group Plc (LON:RENE) tells Proactive positive long-term data on their CTX cell therapy for stroke has been presented at the American Heart Association International Stroke Conference in Los Angeles.

Professor Keith Muir, of the Queen Elizabeth University Hospital, Glasgow and Principal Investigator for ReNeuron’s PISCES II study, told the audience that upper limb functional recovery was “durable and maintained” out to 12 months post-treatment.

Quick facts: ReNeuron Group PLC

Price: 117 GBX

LSE:RENE
Market: LSE
Market Cap: £37.26 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ReNeuron signs retinal stem cell exclusivity agreement

ReNeuron Group Plc (LON:RENE) has inked a deal worth up to US$5mln ahead of potentially licensing out its ground-breaking its hRPC retinal stem cell technology and therapeutic programmes. CFO Michael Hunt says they're hoping the exclusivity agreement with an unnamed US-based speciality...

on 11/7/18

2 min read